Fortrea Holdings Inc.
A global contract research organization that helps pharmaceutical, biotech, and medical device companies run clinical trials, from early safety studies to final-stage testing. Its roots stretch back to Covance and to a clinical business founded in 1968, and in 2023 it was spun off from the lab giant Labcorp to stand on its own. The name "Fortrea" is a made-up word from that split, likely blending "fortitude" and "trial" — a nod to the strength of the clinical studies it runs.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Vanguard Capital Management | 13GPassive | 5.05% | 4.73M | Apr 29, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| Sessa Capital (Master), L.P. | 13G/APassive | 4.32% | 3.99M | Feb 17, 2026 |
| Sessa Capital GP, LLC | 13G/APassive | 4.32% | 3.99M | Feb 17, 2026 |
| Sessa Capital IM, L.P. | 13G/APassive | 4.32% | 3.99M | Feb 17, 2026 |
| Sessa Capital IM GP, LLC | 13G/APassive | 4.32% | 3.99M | Feb 17, 2026 |
| John Petry | 13G/APassive | 4.32% | 3.99M | Feb 17, 2026 |
| AQR Capital Management, LLC | 13G/APassive | 4.11% | 3.74M | Nov 14, 2025 |
| AQR Capital Management Holdings, LLC | 13G/APassive | 4.11% | 3.74M | Nov 14, 2025 |
| THE GOLDMAN SACHS GROUP, INC. | 13GPassive | 8.9% | 8.03M | Aug 13, 2025 |